Assertio Therapeutics, Inc. Forecast, price target & analysts
Assertio Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Assertio Therapeutics, Inc. Classifications & Recommendation:
Assertio Therapeutics, Inc. Price Target
| Target Price | $3.06 |
| Price | $0.69 |
| Potential |
346.26%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Assertio Therapeutics, Inc. 2026 .
The average Assertio Therapeutics, Inc. target price is $3.06.
This is
346.26%
register free of charge
$3.68
435.95%
register free of charge
$1.52
120.94%
register free of charge
|
|
| A rating was issued by 10 analysts: 9 Analysts recommend Assertio Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Assertio Therapeutics, Inc. stock has an average upside potential 2026 of
346.26%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2031
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 124.96 | 116.00 |
| 17.83% | 7.17% | |
| EBITDA Margin | 5.65% | 9.21% |
| 80.59% | 63.01% | |
| Net Margin | -17.27% | -26.61% |
| 92.09% | 54.09% |
7 Analysts have issued a sales forecast Assertio Therapeutics, Inc. 2025 . The average Assertio Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Assertio Therapeutics, Inc. EBITDA forecast 2025. The average Assertio Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Assertio Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Assertio Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2031
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.23 | -0.32 |
| 95.07% | 39.13% | |
| P/E | negative | |
| EV/Sales | 0.15 |
7 Analysts have issued a Assertio Therapeutics, Inc. forecast for earnings per share. The average Assertio Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Assertio Therapeutics, Inc....
Current Assertio Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 19 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 25 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 19 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 19 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 16 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 25 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
